International Journal of Clinical Case Reports 2024, Vol.14, No.3, 167-177 http://medscipublisher.com/index.php/ijccr 175 References Adams S., Gatti-Mays M., Kalinsky K., Korde L., Sharon E., Amiri-Kordestani L., Bear H., McArthur H., Frank E., Perlmutter J., Page D., Vincent B., Hayes J., Gulley J., Litton J., Hortobagyi G., Chia S., Krop I., White J., Sparano J., Disis M., and Mittendorf E., 2019, Current landscape of immunotherapy in breast cancer: a review, JAMA oncology, 5(8): 1205-1214. https://doi.org/10.1001/jamaoncol.2018.7147 PMid:30973611 PMCid:PMC8452050 Agostinetto E., Montemurro F., Puglisi F., Criscitiello C., Bianchini G., Mastro L., Introna M., Tondini C., Santoro A., and Zambelli A., 2022, Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives, Cancers, 14(9): 2136. https://doi.org/10.3390/cancers14092136 PMid:35565264 PMCid:PMC9105460 Alard E., Butnariu A., Grillo M., Kirkham C., Zinovkin D., Newnham L., Macciochi J., and Pranjol M., 2020, Advances in anti-cancer immunotherapy: car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets, Cancers, 12(7): 1826. https://doi.org/10.3390/cancers12071826 PMid:32645977 PMCid:PMC7408985 Bagchi S., Yuan R., and Engleman E., 2020, Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance, Annual review of pathology, 16: 223-249. https://doi.org/10.1146/annurev-pathol-042020-042741 PMid:33197221 Bai R., Chen N., Li L., Du N., Bai L., Lv Z., Tian H., and Cui J., 2020, Mechanisms of cancer resistance to immunotherapy, Frontiers in Oncology, 10: 1290. https://doi.org/10.3389/fonc.2020.01290 PMid:32850400 PMCid:PMC7425302 Barzaman K., Moradi-Kalbolandi S., Hosseinzadeh A., Kazemi M., Khorramdelazad H., Safari E., and Farahmand L., 2021, Breast cancer immunotherapy: current and novel approaches, International Immunopharmacology, 98: 107886. https://doi.org/10.1016/j.intimp.2021.107886 PMid:34153663 Basu A., Ramamoorthi G., Jia Y., Faughn J., Wiener D., Awshah S., Kodumudi K., and Czerniecki B., 2019, Immunotherapy in breast cancer: current status and future directions, Advances in Cancer Research, 143: 295-349. https://doi.org/10.1016/bs.acr.2019.03.006 PMid:31202361 Bou-Dargham M., Draughon S., Cantrell V., Khamis Z., and Sang Q., 2021, Advancements in human breast cancer targeted therapy and immunotherapy, Journal of Cancer, 12: 6949-6963. https://doi.org/10.7150/jca.64205 PMid:34729098 PMCid:PMC8558657 Bou-Dargham M., Liu Y., Sang Q., and Zhang J., 2018, Abstract P3-05-18: the complex landscape of breast cancer immune evasion and its implications to personalized and combined immunotherapy, Cancer Research, 78 (4_Supplement): P3-05-18. https://doi.org/10.1158/1538-7445.SABCS17-P3-05-18 Darvin P., Toor S., Nair V., and Elkord E., 2018, Immune checkpoint inhibitors: recent progress and potential biomarkers, Experimental and Molecular Medicine, 50(12): 1-11. https://doi.org/10.1038/s12276-018-0191-1 PMid:30546008 PMCid:PMC6292890 Elsas M., Hall T., and Burg S., 2020, Future challenges in cancer resistance to immunotherapy, Cancers, 12(4): 935. https://doi.org/10.3390/cancers12040935 PMid:32290124 PMCid:PMC7226490 Ende N., Nguyen A., Jager A., Kok M., Debets R., and Deurzen C., 2023, Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review, International Journal of Molecular Sciences, 24(3): 2969. https://doi.org/10.3390/ijms24032969 PMid:36769287 PMCid:PMC9918290 Esteva F., Hubbard-Lucey V., Tang J., and Pusztai L., 2019, Immunotherapy and targeted therapy combinations in metastatic breast cancer, The Lancet, Oncology, 20(3): e175-e186. https://doi.org/10.1016/S1470-2045(19)30026-9 PMid:30842061 Gajewski T., 2015, The next hurdle in cancer immunotherapy: overcoming the non-t-cell-inflamed tumor microenvironment, Seminars in Oncology, 42(4): 663-671. https://doi.org/10.1053/j.seminoncol.2015.05.011 PMid:26320069 PMCid:PMC4555998 García-Aranda M., and Redondo M., 2019, Immunotherapy: a challenge of breast cancer treatment, Cancers, 11(12): 1822. https://doi.org/10.3390/cancers11121822 PMid:31756919 PMCid:PMC6966503
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==